Actualités Endo International PLC - ENDP | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting PR Newswire DUBLIN...

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, Aug. 8, 2023 DUBLIN, Aug. 8, 2023...

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Endo Launches Bivalirudin Injection in Ready-to-Use Vials PR Newswire DUBLIN, July 18, 2023 Only ready-to-use...

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting PR Newswire DUBLIN, July...

Current Report Filing (8-k)

0001593034 false 0001593034 2023-06-28 2023-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only...

Current Report Filing (8-k)

0001593034false00015930342023-05-082023-05-08UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549_______________________________FO...

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, May 8, 2023 DUBLIN, May 8, 2023...

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program PR...

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension PR Newswire DUBLIN, April...

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in...

Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules

Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules PR...

Annual Report (10-k)

false2022FY0001593034http://fasb.org/us-gaap/2022#BusinessCombinationAcquisitionRelatedCostshttp://fasb.org/us-gaap/2022#BusinessCombinationAcquisi...

Current Report Filing (8-k)

0001593034 false 0001593034 2023-03-03 2023-03-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Endo International PLC (ENDP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Endo International PLC (ENDP) Actualités

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

Current Report Filing (8-k)

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Current Report Filing (8-k)

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules

Annual Report (10-k)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Endo International PLC (ENDP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Endo International PLC (ENDP) Actualités

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

Current Report Filing (8-k)

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Current Report Filing (8-k)

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules

Annual Report (10-k)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités